Caris Life Sciences stock
Private-market facts for current and former Caris Life Sciences employees researching their stock.
Overview
Caris Life Sciences is a molecular profiling company that provides comprehensive tumor profiling tests to help oncologists identify the most effective therapies for cancer patients based on genomic, transcriptomic, and proteomic data.
Selling Caris Life Sciences shares
Why shareholders consider selling
Shareholders in Caris Life Sciences may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Caris Life Sciences does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Caris Life Sciences stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Caris Life Sciences shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Caris Life Sciences shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series E round and its reported $7.5B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Caris Life Sciences shareholders
Exploring equity in Caris Life Sciences often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Caris Life Sciences most recently raised a Series E round in January 2024. The company was valued at $7.5B. Total funding raised to date is approximately $1.3B.
Founders & company background
Caris Life Sciences was founded in 2008 by David Halberstam and is headquartered in Irving, TX.
Industry
Similar private companies
Latest Caris Life Sciences news
Frequently asked questions
- Is Caris Life Sciences still a private company?
- Yes, Caris Life Sciences is currently a private company.
- What is Caris Life Sciences's latest funding round?
- Caris Life Sciences's most recent known round is Series E, raised in January 2024.
- What is Caris Life Sciences's valuation?
- Caris Life Sciences's latest reported valuation is $7.5B.
- Who are the investors in Caris Life Sciences?
- Investor information is not currently available.
- Can I sell my Caris Life Sciences stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Caris Life Sciences stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Caris Life Sciences data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.